Circulating blood platelets contain small numbers of fully functional mitochondria. Accumulating evidence demonstrates that these mitochondria regulate the pro-thrombotic function of platelets through not only energy generation, but also redox signalling and the initiation of apoptosis. Beyond its regulation of haemostasis, platelet mitochondrial function has also traditionally been used to identify and study mitochondrial dysfunction in human disease, owing to the easy accessibility of platelets compared with other metabolically active tissues. In the present article, we provide a brief overview of what is currently known about the function of mitochondria in platelets and review how platelet mitochondria have been used to study mitochondrial function in human disease.
Introduction
The traditional view of the mitochondrion as the 'powerhouse' of the cell has greatly evolved over the last few decades. It is now clear that mitochondria are not only essential for energy homoeostasis in most cell types, but that the organelle also regulates intracellular signalling through the production of ROS (reactive oxygen species) and initiates apoptosis through the release of cytochrome c [1, 2] . Notably, although much is known about the role of mitochondria in metabolically active tissues such as the brain, heart and liver, the purpose of the mitochondrion in circulating blood cells, such as the platelet, remains elusive. Platelets, although anucleate, contain small numbers of fully functional mitochondria. Whereas it was previously thought that these mitochondria existed solely to fuel platelet-mediated aggregation, it is now apparent that platelet mitochondria are essential in non-ATPmediated thrombotic signalling as well as in platelet apoptosis [3] [4] [5] . Interestingly, despite the lack of knowledge about the exact function that mitochondria serve in platelets, these cells have long been interesting to investigators as an easily accessible source of human mitochondria. Measurement of platelet mitochondrial function has been used as a biomarker of disease, as well as a surrogate for mitochondrial activity in more difficult to access tissues [6] [7] [8] [9] [10] [11] [12] . In the present study, we provide a brief overview of what is currently known about the function of mitochondria in platelets and review how platelet mitochondria have been used to study mitochondrial function in human disease.
oval-shaped cells that rapidly undergo a morphological transformation, emitting long protrusions and forming large aggregates on injured vessels. Since then, the role of the platelet in thrombus formation has been largely elucidated. In physiological conditions, platelets circulate close to the endothelium, but adherence is prevented by blood flow as well as endothelially derived secreted anti-coagulatory factors. However, after vascular injury platelets initiate a rapid and complex signalling cascade that may be divided into three major stages [14, 15] . In the first step, platelets adhere to the compromised endothelium through the interaction of specific surface receptors with exposed subendothelial components including von Willebrand factor, collagen, fibronectin, thrompospondin and laminin. In the second step, platelet aggregation, is mediated primarily by thrombin and ADP binding to G-protein-coupled receptors on the surface of the platelet, which initiates a number of signalling cascades within the cell. These signalling cascades, including the inhibition of phospholipase C and activation of phosphoinositide 3-kinase, ultimately cause the platelet to change shape as well as induce activation and attachment of other platelets. In the final step, platelets release soluble factors including ADP from their granules and express inflammatory mediators. Additionally, expression of surface glycoprotein IIb/IIIa is increased to enable interaction between platelets and mediate aggregation and ultimately thrombus formation [14, 15] .
Mitochondrial regulation of platelet activation and apoptosis
Although platelets contain a relatively small number of mitochondria, these cells have a greater rate of ATP turnover than resting mammalian muscle, suggesting they are fairly metabolically active [16] . Platelet activation and granule secretion are energy-consuming processes and derive their ATP from both glycolysis and oxidative phosphorylation. It is estimated that resting platelets derive approximately 60% of their ATP from glycolysis, whereas aerobic respiration accounts for 30-40% of energy basally. However, during platelet activation and secretion, the rate of both glycolysis and aerobic respiration increase significantly to accommodate escalated energy demand [17, 18] . Similar to other cell types, oxidative phosphorylation and glycolysis are tightly linked in platelets, as pharmacological inhibition of one process has been shown to cause a compensatory increase in the other [18] . Corroborating the essential role of the mitochondrion as an energy supplier during thrombus formation, inhibition of mitochondrial respiration by pharmacological blockers of the electron transport chain, including antimycin A, cyanide or nitric oxide, significantly attenuate granule secretion and aggregation [19, 20] .
Accumulating evidence suggests that mitochondria regulate platelet activation beyond simply providing ATP. Treatment of platelets with exogenous hydrogen peroxide has been shown to lead to activation, and intracellular ROS generation has been implicated as an integral second messenger in collagen-induced activation of platelets [21, 22] . Whereas the exact downstream targets of the ROS are not completely clear, scavenging of intracellular hydrogen peroxide has been shown to activate phospholipase C and arachidonic acid metabolism leading to the inhibition of calcium mobilization, ATP release from granules and platelet aggregation [22] . Although multiple sources of ROS exist within the platelet, the mitochondrial electron transport chain can generate significant concentrations of superoxide, which are rapidly converted into hydrogen peroxide by superoxide dismutase. Production of mitochondrial ROS is closely linked with changes in mitochondrial membrane potential, as increases in membrane potential (hyperpolarization) can increase the reduction of the electron transport chain resulting in the leak of electrons out of the chain and subsequent superoxide generation.
Indeed multiple studies now link increased platelet activation with mitochondrial hyperpolarization and ROS generation [4, 5] . For example, treatment of platelets with opsonized zymosin A, an activator of the complement system, was shown to cause mitochondrial hyperpolarization and increased mitochondrial ROS generation as measured by dihydrorhodamine 123, an effect that was associated with the rearrangement of the platelet cytoskeleton, indicative of activation [4] . Furthermore, aberrant mitochondrial ROS production may underlie pathological platelet activation. For example, it is known that platelets of patients with Type 2 diabetes exhibit increased sensitivity to collagenmediated activation. Brownlee and colleagues demonstrated that hyperglycaemia induces hyperpolarization in normal platelets, resulting in the augmentation of mitochondrial ROS generation and subsequent activation [5] . Additionally, scavenging of these ROS with a superoxide dismutase mimetic prevented hyperglycaemia-induced sensitivity to collagen-mediated activation [5] . Consistent with the idea that increased mitochondrial ROS potentially contributes to increased platelet activation in diabetes, Avila et al. [6] recently showed that platelets from diabetic patients had decreased rates of oxygen consumption and hallmark signs of increased ROS generation.
Although mitochondrial hyperpolarization is associated with platelet activation, the loss of membrane potential is a key step in the initiation of platelet apoptosis. Vanags et al. [23] in 1997 were the first to demonstrate that the mitochondrial apoptotic pathway present in nucleated cells was also active in platelets. This pathway is initiated by stimuli that lead to the collapse of mitochondrial membrane potential, opening of the mitochondrial permeability transition pore and the release of cytochrome c from the mitochondrial matrix to the cytosol. Once in the cytosol, cytochrome c binds to APAF-1 (apoptotic proteinase activating factor-1) to initiate a signalling cascade that promotes caspase-9 autoactivation and subsequent activation of caspase-3, which cleaves cytoskeletal proteins to induce the hallmarks of apoptotic cell death. Additionally, the expression and translocation of a host of pro-and anti-apoptotic Bcl-2 protein family members regulate this intrinsic apoptotic pathway (reviewed in [3] ).
A number of stimuli have been shown to be effective in inducing platelet apoptosis including hydrogen peroxide [24] , thrombin [24, 25] , collagen [26, 27] and extreme shear stress [28] . Notably, several physiological stimuli that cause platelet activation at low concentrations propagate platelet apoptosis at much higher concentrations. This is mechanistically consistent with studies demonstrating that platelet activators increase mitochondrial membrane potential at low concentrations, whereas prolonged exposure to higher concentrations induce the collapse of membrane potential [29] . Physiologically, this type of dual signalling by one stimulus is potentially important in the regulation of coagulation. For example, temporal and spatial concentrations of thrombin vary greatly in the process of thrombus formation, with nanomolar concentrations generated early in the platelet activation phase and significantly higher concentrations present close to a thrombus, where additional platelets may not be needed [30, 31] . Increased platelet apoptosis has been reported in a number of pathologies including Type 2 diabetes [32] , immune thrombocytopenia [33] and malaria [34] (Figure 1 ).
Platelets as a model to measure human mitochondrial function in disease
Since the discovery that platelets contain fully functional mitochondria, there has been interest in the use of these cells to study mitochondrial function in human disease. The abundance of platelets in circulation as well as the relative ease to obtain them through a simple blood draw has made these cells an attractive source of human mitochondria. Indeed, the idea that platelet mitochondria could serve as a surrogate for mitochondrial function in metabolically active organs as well as a biomarker for disease has been tested in a number of patient populations (see Table 1 for a summary).
Figure 1 Mitochondrial regulation of platelet function
The five complexes of the electron transport chain are buried within the inner mitochondrial membrane. Electrons flowing through the chain reduce oxygen at complex IV and generate a membrane potential, which drives ATP production to fuel resting platelets basally (top panel). In response to a mild activating stimulus, the membrane potential increases, augmenting ATP production, oxygen consumption and ROS generation, and results in platelet activation (middle panel). Exposure to a strong activating stimulus or apoptotic stimulus causes membrane potential collapse, release of cytochrome c (c) from the mitochondrion and downstream apoptotic signalling (bottom panel). UQ, ubiquinone.
Electron transport chain activity has been assayed and found to be altered in the platelets of patients of a number of neurological diseases including AD (Alzheimer's disease) [10, 35] , Huntington's disease [8] , schizophrenia [7] , migraine headaches [11] and PD (Parkinson's disease) [9, 36] . Notably, each of these diseases is characterized by a specific pattern of changes in complex activity. For example, whereas platelets from patients with PD demonstrate a deficiency in the activity of complex I, similar to that observed in the dopaminergic neurons of the same patients [9, 36] , patients with schizophrenia show an increase in complex I activity [7] . More profound deficiencies are observed in patients with migraine headaches, who display a decrease in complexes I and IV and citrate synthase activities compared with healthy subjects. Notably, patients with migraine headaches that also have aura have a decrease in complex III activity [11] . These data suggest that alterations in platelet mitochondrial function are specific for different pathologies and can potentially be used as a biomarker of disease.
Owing to their easy accessibility, one major advantage that platelets pose of over other metabolically active tissue such as muscle is the relative ease of measuring mitochondrial function at multiple time points after a systemic intervention. For example, patients with AD demonstrate no change in complex I activity but decreased neuronal and platelet complex IV activity [37] . To test the functional implications of this complex IV inhibition, Mancuso et al. [38] compared lactate accumulation as a measure of glycolysis in the blood of patients with AD with that in healthy controls at rest and at short intervals of forearm exercise. The authors found greater resting levels of lactate as well as a shift in the anaerobic lactate threshold of patients with AD. Notably, these effects correlated inversely with the level of complex IV activity, consistent with a decrease in oxidative phosphorylation and increased glycolysis in these patients [38] . In a more chronic study, platelet mitochondrial respiration was measured in otherwise normal subjects with sepsis over 1 week [12] . Comparison of respiratory capacity Cigarette smoking Complex I decrease [56] and uncoupled respiratory rates over 7 days demonstrated that uncoupled respiratory rate and maximal respiratory capacity increases as sepsis progressed. Notably, sepsis nonsurvivors had a larger increase in respiratory capacity on day 7 compared with survivors, suggesting that platelet mitochondrial function correlates and can potentially be used as a biomarker for the severity of sepsis [12] . These studies demonstrate the utility of platelets in the measurement of human mitochondrial function over time.
Beyond the measurement of mitochondrial function in patients with disease, owing to its lack of a nucleus, the platelet provides a unique source of mitochondrial DNA for in vitro study through the generation of cytoplasmic hybrid (cybrid) cell lines. These cells lines are derived by fusing platelets containing the mitochondria of interest with traditional cells lines that have been depleted of mitochondrial DNA (rho 0 cells) and result in a cybrid cell harbouring the mitochondria of interest on an otherwise normal cytoplasmic and nuclear background [39] . This approach grants the ability to determine the functional consequence of a specific mitochondrial defect on molecular signalling within the cell and is particularly valuable given the difficulty in manipulating the mitochondrial genome by traditional molecular approaches (for a review see [40] ). In practice, the generation of cybrids from platelets of normal subjects and patients with known mitochondrial mutations results in cells with an identical cytoplasmic and nuclear background in which differences in signalling and phenotype are owing solely to mitochondrial abnormalities arising from the disease. For example, cybrid cells in which mitochondria from platelets of patients with idiopathic PD are transferred to rho 0 cells made from the SH-SY5Y neuronal [41] or A549 human lung cell lines [42] demonstrate a significant decrease in complex I activity compared with cybrids derived from healthy subject platelets, consistent with the transfer of mitochondrial DNA. Cybrids have been heavily used to screen for mitochondrial aberrations in diseases and after exposure to environmental stimuli as well as to demonstrate the functional consequence of a known mitochondrial mutation [40, 43] .
Conclusions
It is now clear that mitochondria regulate much more than energy homoeostasis within the platelet. Mitochondrial redox signalling and initiation of apoptosis are important in the pro-thrombotic function of platelets. Furthermore, platelets are a valuable tool to study human mitochondria. The rapid advancement of our understanding of platelet mitochondrial biology not only provides information about the mechanisms governing haemostasis, but also contributes to our ability to translate mitochondrial research to human disease. 
